M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer

Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macrophage or “M1...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshi, Masanori, Tokumaru, Yoshihisa, Asaoka, Mariko, Yan, Li, Satyananda, Vikas, Matsuyama, Ryusei, Matsuhashi, Nobuhisa, Futamura, Manabu, Ishikawa, Takashi, Yoshida, Kazuhiro, Endo, Itaru, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538579/
https://www.ncbi.nlm.nih.gov/pubmed/33024179
http://dx.doi.org/10.1038/s41598-020-73624-w
_version_ 1783590893668794368
author Oshi, Masanori
Tokumaru, Yoshihisa
Asaoka, Mariko
Yan, Li
Satyananda, Vikas
Matsuyama, Ryusei
Matsuhashi, Nobuhisa
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Endo, Itaru
Takabe, Kazuaki
author_facet Oshi, Masanori
Tokumaru, Yoshihisa
Asaoka, Mariko
Yan, Li
Satyananda, Vikas
Matsuyama, Ryusei
Matsuhashi, Nobuhisa
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Endo, Itaru
Takabe, Kazuaki
author_sort Oshi, Masanori
collection PubMed
description Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macrophage or “M1”/“M2” ratio and the tumor immune microenvironment by analyzing the transcriptome of publicly available cohorts, TCGA and METABRIC. We found that “M1” high tumors were not associated with prolonged survival compared with “M1” low tumors, or with the response to neoadjuvant chemotherapy. “M1” high tumors were associated with clinically aggressive features and “M1” high tumors enriched the cell proliferation and cell cycle related gene sets in GSEA. At the same time, “M1” high tumors were associated with high immune activity and favorable tumor immune microenvironment, as well as high expression of immune check point molecules. Strikingly, all these results were mirrored in “M1”/“M2” ratio high tumors. In conclusion, transcriptomically defined “M1” or “M1”/“M2” high tumors were associated with aggressive cancer biology and favorable tumor immune microenvironment but not with survival benefit, which resembled only part of their conventional clinical characteristics.
format Online
Article
Text
id pubmed-7538579
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75385792020-10-07 M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer Oshi, Masanori Tokumaru, Yoshihisa Asaoka, Mariko Yan, Li Satyananda, Vikas Matsuyama, Ryusei Matsuhashi, Nobuhisa Futamura, Manabu Ishikawa, Takashi Yoshida, Kazuhiro Endo, Itaru Takabe, Kazuaki Sci Rep Article Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macrophage or “M1”/“M2” ratio and the tumor immune microenvironment by analyzing the transcriptome of publicly available cohorts, TCGA and METABRIC. We found that “M1” high tumors were not associated with prolonged survival compared with “M1” low tumors, or with the response to neoadjuvant chemotherapy. “M1” high tumors were associated with clinically aggressive features and “M1” high tumors enriched the cell proliferation and cell cycle related gene sets in GSEA. At the same time, “M1” high tumors were associated with high immune activity and favorable tumor immune microenvironment, as well as high expression of immune check point molecules. Strikingly, all these results were mirrored in “M1”/“M2” ratio high tumors. In conclusion, transcriptomically defined “M1” or “M1”/“M2” high tumors were associated with aggressive cancer biology and favorable tumor immune microenvironment but not with survival benefit, which resembled only part of their conventional clinical characteristics. Nature Publishing Group UK 2020-10-06 /pmc/articles/PMC7538579/ /pubmed/33024179 http://dx.doi.org/10.1038/s41598-020-73624-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Oshi, Masanori
Tokumaru, Yoshihisa
Asaoka, Mariko
Yan, Li
Satyananda, Vikas
Matsuyama, Ryusei
Matsuhashi, Nobuhisa
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Endo, Itaru
Takabe, Kazuaki
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title_full M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title_fullStr M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title_full_unstemmed M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title_short M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
title_sort m1 macrophage and m1/m2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538579/
https://www.ncbi.nlm.nih.gov/pubmed/33024179
http://dx.doi.org/10.1038/s41598-020-73624-w
work_keys_str_mv AT oshimasanori m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT tokumaruyoshihisa m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT asaokamariko m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT yanli m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT satyanandavikas m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT matsuyamaryusei m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT matsuhashinobuhisa m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT futamuramanabu m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT ishikawatakashi m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT yoshidakazuhiro m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT endoitaru m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer
AT takabekazuaki m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer